↓ Skip to main content

Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer

Overview of attention for article published in Breast Cancer Research and Treatment, October 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
29 Mendeley
Title
Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer
Published in
Breast Cancer Research and Treatment, October 2013
DOI 10.1007/s10549-013-2720-x
Pubmed ID
Authors

Diana S. M. Buist, Jaclyn L. F. Bosco, Rebecca A. Silliman, Heather Taffet Gold, Terry Field, Marianne Ulcickas Yood, Virginia P. Quinn, Marianne Prout, Timothy L. Lash, The Breast Cancer Outcomes in Older Women (BOW) Investigators

Abstract

Annual surveillance mammograms in older long-term breast cancer survivors are recommended, but this recommendation is based on little evidence and with no guidelines on when to stop. Surveillance mammograms should decrease breast cancer mortality by detecting second breast cancer events at an earlier stage. We examined the association between surveillance mammography beyond 5 years after diagnosis on breast cancer-specific mortality in a cohort of women aged ≥ 65 years diagnosed 1990-1994 with early stage breast cancer. Our cohort included women who survived disease free for ≥ 5 years (N = 1,235) and were followed from year 6 through death, disenrollment, or 15 years after diagnosis. Asymptomatic surveillance mammograms were ascertained through medical record review. We used Cox proportional hazards regression stratified by follow-up year to calculate the association between time-varying surveillance mammography and breast cancer-specific and other-than-breast mortality adjusting for site, stage, primary surgery type, age and time-varying Charlson Comorbidity Index. The majority (85 %) of the 1,235 5-year breast cancer survivors received ≥ 1 surveillance mammogram in years 5-9 (yearly proportions ranged from 48 to 58 %); 82 % of women received ≥ 1 surveillance mammogram in years 10-14. A total of 120 women died of breast cancer and 393 women died from other causes (average follow-up 7.3 years). Multivariable models and lasagna plots suggested a modest reduction in breast cancer-specific mortality with surveillance mammogram receipt in the preceding year (IRR 0.82, 95 % CI 0.56-1.19, p = 0.29); the association with other-cause mortality was 0.95 (95 % CI 0.78-1.17, p = 0.64). Among older breast cancer survivors, surveillance mammography may reduce breast cancer-specific mortality even after 5 years of disease-free survival. Continuing surveillance mammography in older breast cancer survivors likely requires physician-patient discussions similar to those recommended for screening, taking into account comorbid conditions and life-expectancy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ecuador 2 7%
United States 1 3%
Brazil 1 3%
Unknown 25 86%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 24%
Student > Ph. D. Student 3 10%
Professor > Associate Professor 3 10%
Student > Master 3 10%
Student > Postgraduate 2 7%
Other 6 21%
Unknown 5 17%
Readers by discipline Count As %
Medicine and Dentistry 16 55%
Nursing and Health Professions 3 10%
Mathematics 1 3%
Psychology 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Other 0 0%
Unknown 7 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2013.
All research outputs
#14,636,949
of 22,727,570 outputs
Outputs from Breast Cancer Research and Treatment
#3,164
of 4,648 outputs
Outputs of similar age
#123,098
of 210,284 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#44
of 65 outputs
Altmetric has tracked 22,727,570 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,648 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,284 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.